Tetra Pharm Technologies, a Copenhagen, Denmark-based biotech company focused on therapeutics targeting the endocannabinoid system, raised €9M in Series A funding.
The round was led by a group of Danish investors. Its shareholders include including Leafy Tunnel, Enexis, Rump Invest, Nesroht Holding and Ole GS Holding.
The company intends to use the funds to increase its capacity in research and development and expand its commercial operations internationally.
Led by CEO Martin Rose, Tetra Pharm Technologies is a biopharmaceutical company focused on therapeutics targeting the endocannabinoid system to treat neuropathic pain and mental health disorders.
During 2022, the company closed several significant distribution deals across their main markets in Europe, and they expect to release its first product to treat neuropathic pain in February 2023.
FinSMEs
26/01/2023